Related Experiment Videos

Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis

B Hess1, Y Nakagawa, J H Parks

  • 1Nephrology Program, Pritzker School of Medicine, University of Chicago, Illinois 60637.

Insights

Tamm-Horsfall glycoprotein (THP) from kidney stone patients shows reduced ability to prevent calcium oxalate crystal aggregation. This impaired function is linked to abnormal self-aggregation of THP, potentially contributing to stone formation.

Area of Science:

  • Nephrology
  • Biochemistry
  • Crystallography

Background:

  • Tamm-Horsfall glycoprotein (THP) is a key urinary protein.
  • THP naturally inhibits calcium oxalate monohydrate (COM) crystal aggregation.
  • This inhibition is crucial for preventing kidney stones (nephrolithiasis) and nephrocalcinosis.

Purpose of the Study:

  • To investigate the inhibitory function of THP in patients with severe nephrolithiasis.
  • To determine if abnormalities in THP contribute to kidney stone formation.

Main Methods:

  • Studied THP from six nephrolithiasis patients and compared its function to normal THP.
  • Assessed THP's ability to inhibit COM crystal self-aggregation under simulated urine conditions (pH, NaCl, THP concentration).
  • Evaluated THP self-aggregation properties.

Main Results:

  • THP from nephrolithiasis patients exhibited significantly less inhibition of COM crystal aggregation compared to normal THP.
  • Patient THP showed enhanced self-aggregation, reducing its availability for crystal interaction.
  • Abnormal THP function was observed in a familial pattern, affecting a father and his oldest son.

Conclusions:

  • Reduced THP inhibitory function, due to enhanced THP self-aggregation, may be a factor in severe nephrolithiasis.
  • Familial aggregation of abnormal THP suggests a potential genetic component in THP dysfunction and kidney stone risk.

Related Concept Videos